{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:45:58Z","timestamp":1792381558096,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.hoc.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T16:52:58Z","timestamp":1490287978000},"page":"223-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Angioimmunoblastic T-Cell Lymphoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.12.001_bib1","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","article-title":"Angioimmunoblastic lymphadenopathy with dysproteinaemia","volume":"1","author":"Frizzera","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.12.001_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197501022920101","article-title":"Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin\u2019s disease","volume":"292","author":"Lukes","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.12.001_bib3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/1097-0142(197802)41:2<578::AID-CNCR2820410226>3.0.CO;2-8","article-title":"Malignant lymphoma arising in angioimmunoblastic lymphadenopathy","volume":"41","author":"Nathwani","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.12.001_bib4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib6","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib8","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.12.001_bib9","series-title":"World Health Organization classification of tumors of haematopoietic and lymphoid tissues","first-page":"309","article-title":"Angioimmunoblastic T-cell lymphoma","author":"Dogan","year":"2008"},{"key":"10.1016\/j.hoc.2016.12.001_bib10","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000478-200604000-00009","article-title":"Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL)","volume":"30","author":"Dupuis","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.hoc.2016.12.001_bib12","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.1158\/0008-5472.CAN-07-1708","article-title":"Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation","volume":"67","author":"Piccaluga","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2016.12.001_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2009.019133","article-title":"A\u00a0novel subset of T-helper cells : follicular T-helper cells and their markers","volume":"95","author":"Laurent","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.12.001_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2559.2011.03981.x","article-title":"Peripheral T\u00a0cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert\u2019s personal archive","volume":"59","author":"Agostinelli","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.hoc.2016.12.001_bib15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2015-08-665075","article-title":"Follicular helper T\u00a0cell-related lymphomas","volume":"8","author":"Pileri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2016.12.001_bib17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.12.001_bib19","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T\u00a0cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2016.12.001_bib21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A\u00a0targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib22","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T\u00a0cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2016.12.001_bib24","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signalling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib25","series-title":"Postgraduate hematology","first-page":"524","article-title":"T-cell lymphoproliferative disorders","author":"Zinzani","year":"2016"},{"key":"10.1016\/j.hoc.2016.12.001_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/DAD.0000000000000144","article-title":"Cutaneous manifestations of angioimmunoblastic T-cell lymphoma: clinical and pathological characteristics","volume":"37","author":"Botros","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.hoc.2016.12.001_bib27","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib28","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T\u00a0cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.12.001_bib29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: a review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2016.12.001_bib30","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T\u00a0cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2016.12.001_bib31","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicentre cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicentre study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib33","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2016.12.001_bib34","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib35","first-page":"1272","article-title":"Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation","volume":"88","author":"Schetelig","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.12.001_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0609.2007.00815.x","article-title":"Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience","volume":"78","author":"Rodr\u00edguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2016.12.001_bib37","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicentre cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib39","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2016.12.001_bib40","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T\u00a0cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.12.001_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/10428190601137658","article-title":"Angioimmunoblastic T\u00a0cell lymphoma: treatment experience with cyclosporine","volume":"48","author":"Advani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.12.001_bib43","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib46","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib47","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","author":"Pro","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib48","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib49","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.12.001_bib50","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A\u00a0phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2016.12.001_bib51","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.12.001_bib52","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib53","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib54","doi-asserted-by":"crossref","unstructured":"O\u2019Connor OA, \u00d6zcan M, Jacobsen ED, et\u00a0al. First multicentre, randomized phase 3 study in patients (pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator\u2019s choice (Lumiere trial; NCT01482962). In: 57th ASH annual meeting abstracts. Orlando, December 5\u20138, 2015. [abstract: 341].","DOI":"10.1182\/blood.V126.23.341.341"},{"key":"10.1016\/j.hoc.2016.12.001_bib55","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphoma in adults: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib56","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib57","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.12.001_bib58","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patientswith peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.12.001_bib59","doi-asserted-by":"crossref","unstructured":"Johnston PB, Cashen AF, Nikolinakos PG, et\u00a0al. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase 1 trial. In: 57th ASH annual meeting abstracts. Orlando, December 5\u20138, 2015. [abstract: 253].","DOI":"10.1182\/blood.V126.23.253.253"},{"key":"10.1016\/j.hoc.2016.12.001_bib60","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.12.001_bib61","unstructured":"d\u2019Amore F, Lepp\u00e4 S, Gomes da Silva M, et\u00a0al. First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated with high dose therapy. In: 54th ASH annual meeting abstracts. Atlanta, December 8\u201311, 2012. [abstract: 57]."},{"key":"10.1016\/j.hoc.2016.12.001_bib62","doi-asserted-by":"crossref","unstructured":"Trumper LH, Wulf G, Ziepert M, et\u00a0al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase 3 trial. In: 2016 ASCO annual meeting. Chicago, June 3\u20137, 2016. [abstract: 7500].","DOI":"10.1200\/JCO.2016.34.15_suppl.7500"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:30Z","timestamp":1760184270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0889858816301861"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.12.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angioimmunoblastic T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}